News and Announcements
Newground Capital 222% YoY AUM Growth & Expands to Melbourne
- Published December 20, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2017 was a year of growth and milestones for Newground Capital in its pursuit to become a leading real estate private debt and equity investor.
Noteworthy highlights include:
- 222% YoY AUM growth across $268m total project value across 17 individual financing facilities.
- First institutional mandate signed
- Appointment of ex ANZ Executive Stephen Hall as Head of Real Estate Finance
- Expanded footprint into Melbourne complimenting existing Sydney & Brisbane offices
- Reviewed 90 genuine transactions worth over $2.5b
- 2018 deal pipe includes childcare, fuel, medical, mixed-use and residential projects
The Australian real estate lending market is expected to remain challenging in 2018 with the major banks continuing to reduce exposures to CRE debt in response to various market, regulatory and political pressures.
Newground is well placed to capitalise on the market conditions providing developers with flexible funding solutions whilst also delivering exceptional risk adjusted returns to private capital looking for defensive investment alternatives.
About Newground Capital
Newground Capital invest in compelling opportunistic and value-add real estate investments with a clear exit strategy and attractive risk adjusted return. Newground Capital manage capital on behalf of both Private and Institutional investors located across the globe. The Executive team has 100+ years of combined track record in successfully acquiring, fixing and exiting over $3B in level real estate investments across several sectors.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
